Core Insights - Altimmune (ALT) is focusing on pemvidutide as the central element of its equity story, targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) with a balanced 1:1 glucagon/GLP-1 dual receptor agonist [1] Company Developments - The company has no product revenue base, leading to stock trading based on clinical execution and funding optics, with significant milestones expected in 2026 [2] - ALT plans to initiate a global phase III program in MASH in 2026, aiming for accelerated approval based on biopsy co-primary endpoints [3] - The phase II RECLAIM study for AUD is expected to yield top-line data in Q3 2026, which is seen as a key catalyst for the stock [5][6] - Enrollment for the phase II RESTORE study in ALD is anticipated to complete later in 2026, with challenges noted in patient recruitment [4][8] Financial Position - Altimmune ended 2025 with $274 million in cash, which increased to approximately $340 million by late February 2026 following a $75 million direct offering [10] - The company has access to a $125 million credit facility and projects a cash runway into 2028, although additional funding will likely be needed as phase III spending increases [12][11] Competitive Landscape - Pemvidutide faces competition in AUD from approved options like Vivitrol and generics such as naltrexone and acamprosate, as well as newer approaches under development [7] - In MASH, the competitive landscape includes GLP-1 drugs and other therapies, with major players like Novo Nordisk and Eli Lilly actively involved [15] - The ALD market also features various development activities, including FGF-21 and GLP-1 approaches, indicating a crowded competitive environment [16]